SCHEDULE: RTW Investments Discloses 5.9% Stake in RAPT Therapeutics

RTW Investments, LP and Roderick Wong, M.D. have reported a 5.9% beneficial ownership stake in RAPT Therapeutics, Inc. common stock.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13G.
• The Reporting Persons beneficially own 1,637,165 shares of RAPT Therapeutics, Inc. Common Stock.
• This ownership represents 5.9% of the company's outstanding common stock.
• The percentage is calculated based on 27,710,871 shares outstanding as of November 3, 2025, as reported in RAPT Therapeutics' Form 10-Q.
• RTW Investments, LP is an investment adviser to certain funds (the "RTW Funds"), which directly hold the shares.
• Dr. Roderick Wong is the Managing Partner and Chief Investment Officer of RTW Investments.
• The Reporting Persons share both voting and dispositive power over the 1,637,165 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. The disclosure of a significant beneficial ownership stake by a reputable investment firm like RTW Investments suggests a vote of confidence in RAPT Therapeutics, which can be a positive signal for other investors.

Positives

• A significant beneficial ownership stake (5.9%) by a specialized investment firm like RTW Investments, LP, which focuses on life sciences, can signal institutional confidence in RAPT Therapeutics' long-term prospects and valuation.
• The filing confirms that the shares are held in the ordinary course of business, indicating a strategic investment rather than an activist intent to influence control.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that investment firms specializing in life sciences, such as RTW Investments, often conduct extensive due diligence before taking significant stakes in biotechnology companies. Their investment in RAPT Therapeutics could be viewed in the broader context of strategic positioning within the biopharmaceutical sector, potentially signaling belief in RAPT's pipeline or market position relative to peers.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor may positively influence market perception and potentially stabilize or increase share price due to perceived validation of the company's value.

Key Dates

Recommendation

A Schedule 13G filing primarily reports beneficial ownership and does not provide comprehensive financial or operational data to warrant a strong buy or sell recommendation. However, the significant stake taken by a specialized life sciences investment firm like RTW Investments, LP, suggests institutional confidence in RAPT Therapeutics. This could be a positive indicator for existing shareholders and potential investors, suggesting a 'hold' position to observe future developments and company performance.

Keywords

RAPT Therapeutics, RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals